Analyzing Ampio Pharmaceuticals (NYSE:AMPE) & Vincerx Pharma (NASDAQ:VINC)

Risk and Volatility

Ampio Pharmaceuticals has a beta of 5.57, meaning that its stock price is 457% more volatile than the S&P 500. Comparatively, Vincerx Pharma has a beta of 1.57, meaning that its stock price is 57% more volatile than the S&P 500.

Insider and Institutional Ownership

5.7% of Ampio Pharmaceuticals shares are held by institutional investors. Comparatively, 44.0% of Vincerx Pharma shares are held by institutional investors. 3.3% of Ampio Pharmaceuticals shares are held by insiders. Comparatively, 15.6% of Vincerx Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Ampio Pharmaceuticals and Vincerx Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ampio Pharmaceuticals	N/A	N/A	-$8.63 million	($11.01)	-0.02
Vincerx Pharma	N/A	N/A	-$40.16 million	($5.31)	0.00

Ampio Pharmaceuticals is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ampio Pharmaceuticals and Vincerx Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ampio Pharmaceuticals	N/A	N/A	N/A
Vincerx Pharma	N/A	-248.33%	-132.73%

About Ampio Pharmaceuticals

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

About Vincerx Pharma

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.